• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Haemonetics Corporation Common Stock (NY:HAE)

    75.07 +0.22 (+0.29%)
    Official Closing Price Updated: 7:00 PM EDT, Jul 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Haemonetics Corporation Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    3 Reasons HAE is Risky and 1 Stock to Buy Instead
    Over the last six months, Haemonetics’s shares have sunk to $75.12, producing a disappointing 7.2% loss - a stark contrast to the S&P 500’s 6.1% gain. This m... 
    Via StockStory
    Topics Stocks Supply Chain
    News headline image
    3 Profitable Stocks We Find Risky
    While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
    Via StockStory
    News headline image
    Haemonetics (HAE) Stock Is Up, What You Need To Know
    What Happened? Shares of blood products company Haemonetics (NYSE:HAE) jumped 4.1% in the afternoon session after BofA Securities upgraded its rating on the ... 
    Via StockStory
    News headline image
    Medical Devices & Supplies - Specialty Stocks Q1 Highlights: Haemonetics (NYSE:HAE)
    As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
    Via StockStory
    Haemonetics (NYSE:HAE) Passes the Caviar Cruise Quality Test ↗
    Via Chartmill
    News headline image
    3 Russell 2000 Stocks That Concern Us
    The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
    Via StockStory
    News headline image
    3 Small-Cap Stocks We’re Skeptical Of
    Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
    Via StockStory
    News headline image
    Haemonetics Q4 Earnings Call Highlights ↗
    Haemonetics (NYSE:HAE) reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Haemonetics (HAE) Q4 2026 Earnings Transcript ↗
    Haemonetics (HAE) Q4 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Haemonetics (NYSE:HAE) Reports Upbeat Q1 CY2026
    Blood products company Haemonetics (NYSE:HAE). reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.8% year on year to $346.4 m... 
    Via StockStory
    News headline image
    Haemonetics Earnings: What To Look For From HAE
    Blood products company Haemonetics (NYSE:HAE). will be announcing earnings results this Thursday before market hours. Here’s what to expect. Haemonetics beat... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    1 Value Stock on Our Buy List and 2 Facing Headwinds
    Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
    Via StockStory
    Topics ETFs
    News headline image
    What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year ↗
    This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers worldwide. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    2 Healthcare Stocks with Solid Fundamentals and 1 Facing Challenges
    Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have se... 
    Via StockStory
    News headline image
    A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q4 Earnings: Haemonetics (NYSE:HAE) Vs The Rest Of The Pack
    Via StockStory
    News headline image
    3 Reasons HAE is Risky and 1 Stock to Buy Instead
    Haemonetics’s 21.4% return over the past six months has outpaced the S&P 500 by 15.6%, and its stock price has climbed to $65.64 per share. This was partly d... 
    Via StockStory
    Topics Stocks Supply Chain
    News headline image
    3 Profitable Stocks with Open Questions
    While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
    Via StockStory
    News headline image
    5 Revealing Analyst Questions From Haemonetics’s Q4 Earnings Call
    Haemonetics’ fourth quarter results were met with a negative market reaction, reflecting investor caution despite the company’s performance exceeding Wall Street’s revenue and earnings expectations.... 
    Via StockStory
    Topics Earnings
    News headline image
    HAE Q4 Deep Dive: Plasma Momentum and Hospital Weakness Shape Mixed Results
    Blood products company Haemonetics (NYSE:HAE). announced better-than-expected revenue in Q4 CY2025, but sales fell by 2.7% year on year to $339 million. Its non-GAAP profit of $1.31 per share was 4.8%... 
    Via StockStory
    News headline image
    Haemonetics HAE Q3 2026 Earnings Call Transcript ↗
    Haemonetics HAE Q3 2026 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Haemonetics’s (NYSE:HAE) Q4 CY2025 Sales Top Estimates, Stock Soars
    Blood products company Haemonetics (NYSE:HAE). beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 2.7% year on year to $339 million. Its non-GAAP profit of $1.31 per share was 4.8%... 
    Via StockStory
    News headline image
    What To Expect From Haemonetics’s (HAE) Q4 Earnings
    Blood products company Haemonetics (NYSE:HAE). will be reporting earnings this Thursday before market open. Here’s what to expect. 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Reflecting On Medical Devices & Supplies - Specialty Stocks’ Q3 Earnings: Haemonetics (NYSE:HAE)
    Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - specialty stocks, including Haemonetics (NYSE:HAE) and its peers. 
    Via StockStory
    News headline image
    The Great Mid-Cap Rotation: Fed Rate Cuts Spark a New Bull Run for the 'Forgotten' Middle Market
    As the Federal Reserve transitions from its long-standing "higher-for-longer" stance to a deliberate cycle of monetary easing, the U.S. equity market is witnessing a profound shift in leadership. For... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Supply Chain
    News headline image
    1 Russell 2000 Stock to Keep an Eye On and 2 Facing Headwinds
    The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
    Via StockStory
    News headline image
    3 Value Stocks with Open Questions
    Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
    Via StockStory
    News headline image
    1 Cash-Producing Stock Worth Your Attention and 2 Facing Challenges
    While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
    Via StockStory
    News headline image
    Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    News headline image
    1 Small-Cap Stock Worth Your Attention and 2 We Avoid
    Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
    Via StockStory
    News headline image
    3 Low-Volatility Stocks We Think Twice About
    Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
    Via StockStory
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.